Caroline H. Williams‐Gray

University of Cambridge — United Kingdom

Medicine · Health Sciences

61h-index17.2kcitations205works29.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(147), Neurological disorders and treatments(50), Nuclear Receptors and Signaling(25), Neuroinflammation and Neurodegeneration Mechanisms(24), Alzheimer's disease research and treatments(21)

Publications195 total

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial
The Lancet Neurology·2025· 1 citedOpen Access
Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease
Movement Disorders·2025Open Access
rs6971 TSPO polymorphism in Parkinson's disease
Movement Disorders·2025Open Access
“Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson’s disease”
npj Parkinson s Disease·2025Open Access
Nanoscopic tau aggregates in Parkinson’s disease
2025Open Access
Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson’s disease
Communications Biology·2025· 4 citedOpen Access
Beta-adrenoceptor drugs and progression to Parkinson’s disease milestones in a large pooled incident cohort
npj Parkinson s Disease·2025Open Access
Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease
Movement Disorders·2025· 1 citedOpen Access
Impact of Y chromosome loss on the risk of Parkinson's disease and progression
EBioMedicine·2025· 2 citedOpen Access
Multimodal markers of immune activation predict cognitive outcomes in Parkinson’s disease
Brain Behavior and Immunity·2025· 1 citedOpen Access
The profile of gastrointestinal dysfunction in prodromal to late-stage Parkinson’s disease
npj Parkinson s Disease·2025· 2 citedOpen Access
Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS)
Journal of Parkinson s Disease·2025· 1 citedOpen Access
Peripheral-central immune crosstalk in Parkinson’s disease and its association with clinical severity
Brain Behavior and Immunity·2025· 4 citedOpen Access
Treatment Selection and Prioritization for the <scp>EJS ACT</scp>‐<scp>PD MAMS</scp> Trial Platform
Movement Disorders·2025· 3 citedOpen Access
Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson’s disease
2025· 1 citedOpen Access
The Association between Socioeconomic Deprivation and Long-Term Clinical Outcomes in the Frontotemporal Lobar Degeneration Syndromes and Parkinson's Disease
SSRN Electronic Journal·2025Open Access
The effects of socioeconomic deprivation on long‐term outcomes in Parkinson’s disease and frontotemporal lobar degeneration syndromes
Alzheimer s & Dementia·2024Open Access
Caregiver perspectives enable accurate diagnosis of neurodegenerative disease
Alzheimer s & Dementia·2024· 4 citedOpen Access
ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases
Nature Communications·2024· 24 citedOpen Access
Validation of a 5‐Year Prognostic Model for Parkinson's Disease
Movement Disorders Clinical Practice·2024· 3 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Roger A. Barker(44), Thomas Foltynie(16), Jonathan Evans(14), David J. Burn(11), David P. Breen(11), Clemens R. Scherzer(9), Trevor W. Robbins(8), Sophie Winder‐Rhodes(8), Ganqiang Liu(8), Alexis Brice(8), Stephen Sawcer(7), Jean‐Christophe Corvol(7), Peter Heutink(7), Daniel Weintraub(6), Sarah Mason(6), Ruwani Wijeyekoon(6), Bernard Ravina(6), Jacobus J. van Hilten(6), Andrew Singleton(6), Carol Brayne(5)